Biotech ETF IBB Up 24% in 2026; Moderna Up 587% Despite 18% Drop on Data Leak

4.0 · 7d ago · US · FINANCE

The Facts

  • The iShares Biotechnology ETF (IBB) is up 24% through October 23, 2026, after a 28% gain in 2025. CNBC only
  • Two dozen of IBB's 233 holdings have more than doubled year-to-date. CNBC only
  • Moderna shares are up 587% year-to-date, even after an 18% decline on Thursday following a leak of clinical data for its cancer vaccine. CNBC only
  • Moderna and Merck's mRNA-based melanoma treatment, used with Keytruda, showed a 42% reduction in cancer recurrence or death in Phase 3 results; the companies aim to submit for FDA approval and launch in 2027. CNBC only
  • Eli Lilly's retatrutide cleared two more clinical trials, producing 28%-30% weight loss at the highest doses, per Lilly; the company plans to submit for FDA approval in Q1 2027. CNBC only
Dive deeper · 4 more factsShow less
  • The FDA approved Roche's Enspryng as the first at-home injection for adults with thyroid eye disease. CNBC only
  • AstraZeneca and Amgen reported positive Phase 3 results for Tezspire in severe throat inflammation (eosinophilic esophagitis symptoms described as swallowing symptoms and tissue damage). CNBC only
  • Illumina shares have more than doubled this year and 10x Genomics is up more than 300%. CNBC only
  • The FDA approved 46 novel drugs in 2025, about a dozen of them biologics; roughly 66 novel drugs are in the approval pipeline. CNBC only

Context

Biotech stocks have rallied in 2026, extending gains from 2025, according to CNBC. The sector is recovering from a downturn that followed the Covid era, when vaccine demand fell and higher interest rates slowed IPOs and M&A.

CNBC cites analysts and fund managers attributing the rally to clinical trial results, M&A, and technologies including mRNA, genomics and AI. Drug development remains high-risk, with long timelines and many failures.

How the Agent Panel Scored This

Independent AI personas each scored importance 1–10; the story's score is a trimmed mean (highest and lowest votes dropped). Vote spread: 3.

6 Science & Tech Analyst The story is a market recap covering several concrete events, including a Phase 3 melanoma result with a 42% recurrence reduction, a positive Lilly trial readout, and an FDA at-home injection approval, but these are aggregated within stock-performance coverage and carry moderate rather than major breaking impact.
4 News Editor This is a market-performance roundup mixing a sector ETF gain, a single-stock move, and several clinical and regulatory updates, which are concrete but mostly niche to investors and patients rather than broadly impactful, with a single independent source.
4 Policy Expert The story is primarily a market performance report on ETF and stock gains, with some concrete clinical and regulatory events (an FDA approval of Enspryng, positive Phase 3 data, planned filings) that have limited broad impact, so it rates as minor-to-moderate news.
4 Informed Citizen This is a market recap about biotech stock performance with several concrete trial results and an FDA approval, but these mostly affect investors and a narrow set of patients rather than ordinary people, and the story is largely a performance summary from a single source.
4 Business Analyst This is a market-performance roundup mixing a sector ETF gain with several clinical trial results and an FDA approval, but the concrete events are mostly positive trial data and a single approval with limited broad economic impact, and the Moderna data leak is the only notable market-moving event.
4 Critical Reader This is a market-performance roundup mixing stock moves with several clinical and regulatory developments (Phase 3 results, an FDA approval, and trial readouts), but most items are company announcements or pipeline updates with limited broad impact and the single-source story reports no major verified outcome.
3 Global Affairs Analyst This market-performance story reports ETF gains, stock moves, and several clinical trial and regulatory updates, but these are mostly routine biotech news with limited broad impact on people beyond investors.

Source

← All stories